<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376883</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG 08/00</org_study_id>
    <secondary_id>NCU D3-98</secondary_id>
    <nct_id>NCT00376883</nct_id>
  </id_info>
  <brief_title>Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month</brief_title>
  <official_title>The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Cancer Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Myeloma Study Group</source>
  <brief_summary>
    <textblock>
      Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in
      the bone marrow. Major symptoms are related to the bones due to an increased bone resorption
      and a decreased bone formation leading to bone pain and increased risk of fractures. The
      normal osteoclasts are responsible for bone degradation through stimulation from the
      malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity
      but may have serious side-effects due to renal toxicity and the optimal dose have not been
      established.

      In a randomized double blinded design it is aim to compare the standard of monthly injections
      of 90 mg pamidronate with 30 mg.

      The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12
      months after starting the treatment in newly diagnosed treatment demanding multiple myeloma.
      Secondary end-points are skeletal related events, cost-utility analysis, response, response
      duration and survival and quality of life with respect to fatigue and pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed treatment demanding multiple myeloma are after informed consent
      and approved inclusion criteria randomised by telephone call to Copenhagen Trial Unit (CTU)
      and information on the target dose is send to the distributor, Amgros, and the local pharmacy
      for preparation of the pamidronate solution. Infusion is given for 2½ hours.

      Before starting treatment the patient has to fulfil the first EORTC QLQ-C30 questionnaire
      that is send to the quality of life secretariat in Oslo, Norway. Subsequent questionnaires
      are mailed directly to the patients every third month.

      The infusions are continued for 3 years and may be extended further upon the patient’s
      request.

      Every third month the number of skeletal event, the response and complications are recorded.

      Skeletal X-rays are performed 9 and 24 months after starting the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal related event (time to first SRE)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility analysis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis (conventional chemotherapy vs. high dose chemotherapy with stem cell support)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response, recons duration, survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life estimated by fatigue and pain according to EORTC QLQ-C30</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamidronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosed multiple myeloma with treatment demanding disease

        Exclusion Criteria:

          -  Life-expectancy less than 3 months, another active malignant disease, treatment with
             bisphosphonates for more than 3 months within the last 6 months, patients with
             creatinine above 400 µmol/l 4 weeks after starting chemotherapy, patients who cannot
             cooperate for monthly infusions, patients who do not give their informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gimsing, Ass. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordic Myeloma Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Haematology B, Aalborg Hospital, University of Aarhus</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology L, Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk afd., Århus Universitetshospital</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk seksjon, med avd, Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk avdeling Ullevål Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N - 0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge</name>
      <address>
        <city>Tromsø</city>
        <zip>N-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk seksjon, St.Olav Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetsjukhuset Östra</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologkliniken, Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklin, Universitetssjukhuset MAS,</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklinikken Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Universitetssjukhuset</name>
      <address>
        <city>Örebro</city>
        <zip>SE-70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <last_update_submitted>January 3, 2007</last_update_submitted>
  <last_update_submitted_qc>January 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <keyword>multiple myeloma</keyword>
  <keyword>pamidronate prophylaxis</keyword>
  <keyword>dose comparison</keyword>
  <keyword>quality of life</keyword>
  <keyword>skeletal event</keyword>
  <keyword>response</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

